Search clinical trials for: BIBW 2992 (Afatinib)

Total 2409 results

University of Magdeburg
Boehringer Ingelheim

Terminated

BIBW 2992 (Afatinib) and Vinorelbine

Carcinoma Breast Stage IV

Germany
University of Guadalajara

Completed

Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin

Metabolic Syndrome
Boehringer Ingelheim

Completed

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Breast Neoplasms

Korea, Republic of, Spain, Canada, Germany, Singapore, China, United Kingdom, Taiwan, Israel, United States, Australia, Slovenia, Italy, Brazil, India, Czechia, Netherlands, Ireland, Poland, Belarus, Belgium, Portugal, Russian Federation and more
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

China, Korea, Republic of, Thailand
Boehringer Ingelheim

Completed

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

Breast Neoplasms

France
Johannes Gutenberg University Mainz

Terminated

BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer

Metastatic Disease

Germany
University of Reading

Completed

An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men

Vasodilation

United Kingdom
University of Reading

Unknown

The Vascular and Cognitive Effects of Chronic High-flavanol Intake in Healthy Males

Healthy
Boehringer Ingelheim

Completed

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Spain
Region Skane
Lund University

Completed

Probiotics Against Pathogenic Bacteria in Advanced ENT-Surgery

Advanced ENT Surgery | Microbiological Flora in the Oropharynx and Lower Airways

Sweden
Region Skane
Lund University

Terminated

Probiotics for Reduction of Infections With Clostridium Difficile in Critically Ill Patients (ProbiEnt)

Clostridium Difficile Colonisation | Impact of Enteral Probiotics on Certain Lab Parameters

Sweden
xuexin he

Recruiting

A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone (HER2BAT)

HER2-positive Breast Cancer | Brain Metastases

China
Xiangya Hospital of Central South University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

China
Boehringer Ingelheim

Completed

Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy Volunteers

Healthy
University of California, Davis
National Cancer Institute (NCI)

Completed

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Boehringer Ingelheim

Completed

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Neoplasms

United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

Lymphoma | Leukemia | Hematopoietic and Lymphoid System Neoplasm

United States, Canada
Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
Genentech, Inc.

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Metastatic Prostate Cancer | Advanced Prostate Cancer

Korea, Republic of, United States, Australia
Columbia University
Nemours Children's Clinic; Johns Hopkins All Children's Hospital

Completed

Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Hematopoietic Organs; Disorder

United States
University of Florida

Withdrawn

Explore the Synergy of Combination TKI Therapy

Healthy Volunteers
Boehringer Ingelheim

Withdrawn

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

Pulmonary Disease, Chronic Obstructive | Bronchitis, Chronic

United States, France, Germany
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia

United States
Region Skane
Lund University

Completed

Probiotics Against Pathogenic Bacteria in Connection With Anaesthesia

Oropharyngeal Microbiology

Sweden
Baylor College of Medicine

Recruiting

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Chronic Myeloid Leukemia in Remission

United States
Boehringer Ingelheim

Completed

Effect of BIBW 2948 BS in COPD

Pulmonary Disease, Chronic Obstructive | Bronchitis, Chronic

United States, Germany
Bristol-Myers Squibb

Withdrawn

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

United States
Pusan National University Hospital

Available

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Chronic Myeloid Leukemia
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS for HandiHaler® in Healthy Male Volunteers

Healthy
Azienda Socio Sanitaria Territoriale degli Spedali...

Recruiting

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Leukemia, Chronic Myeloid

Italy
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
University of Liverpool
Imperial College London; Newcastle University; University of Glasgow

Unknown

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)

Chronic Myeloid Leukaemia

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male Volunteers

Healthy
TenNor Therapeutics Limited

Completed

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty

Prosthetic Joint Infection

United States
University of Auckland, New Zealand
Leukaemia & Blood Cancer New Zealand

Active, not recruiting

KISS Study: Kinase Inhibition With Sprycel Start up (KISS)

Chronic Myeloid Leukemia

New Zealand
Bristol-Myers Squibb

Terminated

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Leukemia, Myeloid, Chronic

Sweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
Asan Medical Center

Withdrawn

Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) (IDEAL-E)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Korea, Republic of
Ono Pharma USA Inc

Completed

Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

Healthy

United States
Ono Pharma USA Inc

Completed

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)

Irritable Bowel Syndrome (IBS)

United States
Bristol-Myers Squibb

Terminated

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Leukemia

United States
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Bristol-Myers Squibb

Completed

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Leukemia, Myeloid, Chronic-Phase (CML-CP)
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Bayer

Completed

Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis (Phoenix II)

Dermatitis, Atopic

Germany
National Research Center for Hematology, Russia

Active, not recruiting

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (READIT)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | BCR-ABL Positive Chronic Myelogenous Leukemia

Russian Federation
Norwegian University of Science and Technology

Completed

Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia (NordCML006)

Chronic Myeloid Leukemia

Sweden, Finland, Norway
Mayo Clinic
National Cancer Institute (NCI)

Completed

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb
PPD; ICON Clinical Research; Q2 Solutions; Molecular MD; MultiPharma; Steering Committee and other collaborators

Completed

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

Chronic Phase Chronic Myeloid Leukemia

Italy, Thailand, United States, Belgium, Czechia, Hungary, Argentina, Austria, Brazil, Canada, China, France, Korea, Republic of, Poland, Spain
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Philadelphia-Positive Myeloid Leukemia

Belgium, Spain, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Puerto Rico, Singapore, South Africa, Taiwan, United Kingdom, Australia, France, Philippines, Sweden, Thailand, Russian Federation, China, Poland, Finland, Isra... and more
Newcastle University
Bristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaborators

Completed

Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia (SPIRIT2)

Myeloid Leukemia, Chronic, Chronic Phase

United Kingdom

Search clinical trials for: BIBW 2992 (Afatinib)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations